An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
Study sponsor: Axsome Therapeutics, Inc. · AXSM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-02-17Actual
Enrollment · participants139Actual
Source updated2026-06-25Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.